Key result
A quantitative anti-SRP autoantibody serum ELISA demonstrated 97.1% agreement with immunoprecipitation, with 88% sensitivity and 100% specificity for detecting anti-SRP in myositis.
Why the study?
Does a newly developed anti-SRP ELISA accurately detect anti-SRP autoantibodies compared to immunoprecipitation in patients with myositis?
Observational (n=103)
Does a newly developed anti-SRP ELISA accurately detect anti-SRP autoantibodies compared to immunoprecipitation in patients with myositis?
A newly developed quantitative ELISA for anti-SRP autoantibodies demonstrates high sensitivity and specificity compared to immunoprecipitation and correlates with myositis disease activity.
Answers are grounded in this paper and cite their sources.
May support ELISA as accessible alternative for anti-SRP detection in myositis; leaves open prospective validation before routine use.
OBJECTIVE: The aim of this study was to develop and validate a quantitative anti-signal recognition particle (SRP) autoantibody serum ELISA in patients with myositis and longitudinal association with myositis disease activity. METHODS: We developed a serum ELISA using recombinant purified full-length human SRP coated on ELISA plates and a secondary antibody that bound human IgG to detect anti-SRP binding. Protein immunoprecipitation was used as the gold standard for the presence of anti-SRP. Serum samples from three groups were analysed: SRP(+) myositis subjects by immunoprecipitation, SRP(-) myositis subjects by immunoprecipitation and non-myositis controls. The ELISA's sensitivity, specificity, positive predictive value and negative predictive value were evaluated. Percentage agreement and test-retest reliability were assessed. Serial samples from seven SRP immunoprecipitation-positive subjects were also tested, along with serum muscle enzymes and manual muscle testing. RESULTS: Using immunoprecipitation, we identified 26 SRP(+) myositis patients and 77 SRP(-) controls (including 38 patients with necrotizing myopathy). Non-myositis control patients included SLE (n = 4) and SSc (n = 7) patients. Anti-SRP positivity by ELISA showed strong agreement (97.1%) with immunoprecipitation (κ = 0.94). The sensitivity, specificity, positive predictive value, and negative predictive value of the anti-SRP ELISA were 88, 100, 100 and 96, respectively. The area under the curve was 0.94, and test-retest reliability was strong (r = 0.91, P < 0.001). Serial samples showed that anti-SRP levels paralleled changes in muscle enzymes and manual muscle testing. CONCLUSION: We developed a quantitative ELISA for detecting serum anti-SRP autoantibodies and validated the assay in myositis. Longitudinal assessment of SRP levels by ELISA may be a useful biomarker for disease activity.
No takes yet. Share an insight, caveat, or question.
Aggarwal et al. (2014) conducted an observational in Myositis (n=103). Anti-SRP autoantibody serum ELISA vs. Protein immunoprecipitation was evaluated on Agreement of anti-SRP ELISA with immunoprecipitation (κ = 0.94). A quantitative anti-SRP autoantibody serum ELISA demonstrated 97.1% agreement with immunoprecipitation, with 88% sensitivity and 100% specificity for detecting anti-SRP in myositis.
Synapse has enriched 10 related papers. Consider them for comparative context: